We have developed a new probe for fluorescence in situ hybridization (FISH) which identifies less than 5 Mb of DNA from the terminal q-arm of human chromosome 9. More than 2/3 of the portion of chromosome 9 identified by this probe remains with the 9 in the translocation associated with CML while less than 1/3 becomes part of the Ph chromosome. Experiments on bone marrow samples from normal healthy volunteers and CML patients reveal this probe to be highly effective in detecting the translocation in interphase cells -- two intense domains of fluorescence in normal cells while two intense plus a third less intense domain are present in CML cells. The large size of the probe also enables the detection of the translocation in metaphase cells with high efficiency. Here, we will further increase the efficiency of the probe by essentially eliminating false positives by combining it with a BCR cosmid contig in 2- color FISH, and by reducing the already low percentage of unscorable cells in the cultured preparations. Most importantly we will use the ability of the probe to measure the frequencies of Ph+ cells in quiescent interphase populations as well as cycling metaphase cells in CML patients at diagnosis and at various time points after treatment in order to determine which parameter is most effective in predicting outcome. Patient cadres from all the different treatment regimens associated with this Program will be so evaluated. Data will also be compared and evaluated with the Program Project that will be determining the presence of cells expressing fusion protein in these same patient sets. The FISH probe will also be used to relate the frequency of Ph+ cells before and after autologous bone marrow transplantation to successful outcome. The most efficacious FISH probe system for evaluating the frequency of Ph+ cells will be made available to projects involved in separations of normal from cancer cells or cells of different lineages or proliferative states, and to the Cytogenetics Core for their use in problems associated with this Program.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA049639-07
Application #
5207577
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
7
Fiscal Year
1996
Total Cost
Indirect Cost
Ruvolo, Peter P; Ruvolo, Vivian R; Burks, Jared K et al. (2018) Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865:959-969
Cortes, Jorge E; Gambacorti-Passerini, Carlo; Deininger, Michael W et al. (2018) Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial. J Clin Oncol 36:231-237
Sasaki, Koji; Kantarjian, Hagop; O'Brien, Susan et al. (2018) Prediction for sustained deep molecular response of BCR-ABL1 levels in patients with chronic myeloid leukemia in chronic phase. Cancer 124:1160-1168
Gambacorti-Passerini, Carlo; Cortes, Jorge E; Lipton, Jeff H et al. (2018) Safety and efficacy of second-line bosutinib for chronic phase chronic myeloid leukemia over a five-year period: final results of a phase I/II study. Haematologica 103:1298-1307
Boddu, Prajwal; Shah, Abdul Rashid; Borthakur, Gautam et al. (2018) Life after ponatinib failure: outcomes of chronic and accelerated phase CML patients who discontinued ponatinib in the salvage setting. Leuk Lymphoma 59:1312-1322
Kornblau, Steven M; Ruvolo, Peter P; Wang, Rui-Yu et al. (2018) Distinct protein signatures of acute myeloid leukemia bone marrow-derived stromal cells are prognostic for patient survival. Haematologica 103:810-821
Zhang, Weiguo; Ly, Charlie; Ishizawa, Jo et al. (2018) Combinatorial targeting of XPO1 and FLT3 exerts synergistic anti-leukemia effects through induction of differentiation and apoptosis in FLT3-mutated acute myeloid leukemias: from concept to clinical trial. Haematologica 103:1642-1653
Alhuraiji, Ahmad; Kantarjian, Hagop; Boddu, Prajwal et al. (2018) Prognostic significance of additional chromosomal abnormalities at the time of diagnosis in patients with chronic myeloid leukemia treated with frontline tyrosine kinase inhibitors. Am J Hematol 93:84-90
Ishizawa, Jo; Nakamaru, Kenji; Seki, Takahiko et al. (2018) Predictive Gene Signatures Determine Tumor Sensitivity to MDM2 Inhibition. Cancer Res 78:2721-2731
Boddu, Prajwal; Benton, Christopher B; Wang, Wei et al. (2018) Erythroleukemia-historical perspectives and recent advances in diagnosis and management. Blood Rev 32:96-105

Showing the most recent 10 out of 375 publications